PRAM
Pramlintide
A synthetic analogue of human amylin in which three residues — at positions 25, 28 and 29 — are replaced by the prolines found at those positions in rat amylin. Human amylin aggregates into insoluble fibrils; the proline substitutions are what prevent that. It acts at the amylin receptors.
Pramlintide has 54 registered human studies on ClinicalTrials.gov, reaching phase 4, covering 4,401 planned or enrolled participants across the 53 studies that published a figure. An FDA-approved product contains Pramlintide — SYMLIN (NDA021332). 156 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Pramlintide; the registry search is fuzzy, so every match is re-checked. None of this says whether Pramlintide works or is safe.
FDA status
Approved
Human studies
54
Furthest phase
Phase 4
Papers, 10 yr
156
Readership
628
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
An approved product exists
54
Registered human studies
Phase 4
Furthest phase reached
4,401
Planned or enrolled participants, across 53 studies that published a figure
Approved
FDA-approved product — SYMLIN
64 loose registry matches were checked and 54 confirmed — 10 named something else and were discarded. We count a study only when Pramlintide is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Pramlintide is, and what it has been studied for
Pramlintide is classified by ChEMBL as a protein, and appears in trial registrations under AC-0137 and AC0137. Its FDA substance identifier is D3FM8FA78T.
Across 54 registered trials, it has been studied in Type 1 Diabetes, Obesity, Type 1 Diabetes Mellitus and Diabetes Mellitus, Type 1. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by AstraZeneca and Baylor College of Medicine among others. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Pramlintide reached Phase 4 across 54 registered trials.
An FDA-approved product contains Pramlintide. Approval covers a specific product for a specific use — it is not a verdict on the molecule.
Is anyone studying Pramlintide?
Papers published each year that name Pramlintide in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 22 | 0 | Yes |
| 2018 | 24 | 2 | Yes |
| 2019 | 12 | 2 | Yes |
| 2020 | 18 | 3 | Yes |
| 2021 | 25 | 1 | Yes |
| 2022 | 14 | 1 | Yes |
| 2023 | 9 | 1 | Yes |
| 2024 | 22 | 2 | Yes |
| 2025 | 16 | 1 | Yes |
| 2026 | 12 | 2 | No |
156 papers and 15 registered trials between 2017 and 2026. A paper counts when “Pramlintide” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Pramlintide
156 indexed papers name Pramlintide in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Amylin: Pharmacology, Physiology, and Clinical Potential
- Pramlintide
- Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance
- Pramlintide acetate
- Pramlintide
- Development of Cagrilintide, a Long-Acting Amylin Analogue
- The story of amylin: from physiology to therapy
- Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity
Collected 2026-08-02from PubMed, phrase-matched on “Pramlintide” in title and abstract. Run the same search.
About Pramlintide
A synthetic analogue of human amylin in which three residues — at positions 25, 28 and 29 — are replaced by the prolines found at those positions in rat amylin. Human amylin aggregates into insoluble fibrils; the proline substitutions are what prevent that. It acts at the amylin receptors.
- Also known as
- AC137
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.